Glioblastoma multiforme is an aggressive form of brain cancer that responds poorly to chemotherapy and is generally incurable. The basis for the poor response of this cancer to chemotherapy is not well understood. The atypical protein kinases C (PKCi and PKCf) have previously been implicated in leukaemia cell chemoresistance. To assess the role of atypical PKC in glioblastoma cell chemoresistance, RNA interference was used to deplete human glioblastoma cells of PKCi. Transfection of cells with either of two different RNA duplexes specific for PKCi caused a partial sensitisation to cell death induced by the chemotherapy agent cisplatin. To screen for possible mechanisms for PKCi-mediated chemoresistance, microarray analysis of gene expression was performed on RNA from glioblastoma cells that were either untreated or depleted of PKCi. This identified sets of genes that were regulated either positively or negatively by PKCi. Within the set of genes that were negatively regulated by PKCi, the function of the gene coding for GMFb, an enhancer of p38 mitogen-activated protein kinase (MAP kinase) signaling, was investigated further, as the p38 MAP kinase pathway has been previously identified as a key mediator of cisplatin cytotoxicity. The expression of both GMFb mRNA and protein increased upon PKCi depletion, and this was accompanied by an increase in cisplatin-activated p38 MAP kinase signaling. Transient overexpression of GMFb increased cisplatinactivated p38 MAP kinase signaling and also sensitised cells to cisplatin cytotoxicity. The increase in cisplatin cytotoxicity seen with PKCi depletion was blocked by the p38 MAP kinase inhibitor SKF86002. These data show that PKCi can confer partial resistance to cisplatin in glioblastoma cells by suppressing GMFb-mediated enhancement of p38 MAP kinase signaling.
Introduction
Glioblastoma multiforme is the most common type of brain tumor found in adults. It is usually incurable, and patients have a median survival time after diagnosis of 1 year. Both surgery and radiation increase survival times but are rarely curative, because of local or distant recurrence within the central nervous system. As well, chemotherapy now has an accepted role in the treatment of glioblastoma, with the demonstration that the DNA alkylating agent temozolomide enhances survival (Stupp et al., 2005) . However, the survival benefit with this drug is quite modest, and glioblastoma is resistant to most other standard cancer chemotherapeutics. The basis for this resistance is not fully understood.
In other types of cancers, several studies have linked members of the atypical protein kinase C (PKC) family to chemoresistance (Murray and Fields, 1997; Filomenko et al., 2002) . Primarily this has been studied in leukemia cells, although there is also some evidence that the atypical PKC have a role in colon cancer chemoresistance. A possible role for the atypical PKC in glioblastoma chemoresistance has not been examined. In humans there are two closely related members of the atypical PKC family, designated PKCi and PKCz. Although much of the early literature does not distinguish between these two enzymes, studies in knockout mice now show that they have distinct functions (Soloff et al., 2004) , and perhaps also distinct activation mechanisms. The atypical PKC are both distinguished from other members of the PKC family by their lack of dependence on diacylglycerol for activation; instead they appear to be activated by phosphorylation and by association with different protein complexes. For PKCi (the focus of this paper), activation appears to involve both phosphorylation by phosphoinositide-dependent kinase 1 (PDK1) and an association with an activated member of the Cdc42 family of GTPases (Kanzaki et al., 2004) . PDK1 and Cdc42 are both activated downstream of multiple growth factor receptor tyrosine kinases. For PDK1 this occurs via activation of phosphoinositide 3-kinase (PI 3-kinase) (Vanhaesebroeck and Alessi, 2000) . The epidermal growth factor receptor is frequently activated in glioblastoma by amplification and mutation (Lorimer, 2002) , which leads to constitutive activation of the PI 3-kinase pathway (Moscatello et al., 1998) . Mutations in PTEN, a negative regulator of the PI 3-kinase pathway, are also common in glioblastoma (Sansal and Sellers, 2004) . PKCi could therefore potentially mediate some of the downstream consequences of these oncogenic mutations. Multiple other mechanisms of atypical PKC activation have also been reported (Moscat and Diaz-Meco, 2000) , and there is evidence for kinase-independent signaling functions for the protein as well (Diaz-Meco and Moscat, 2001) . It is generally not clear if these mechanisms are used by both of the atypical PKC, or are PKCz-specific.
The PKC family has at least 13 different family members in total and previously it has been difficult to determine precise roles for its specific members in human cell lines. This paper describes the use of RNA interference to address this problem and assess the role of PKCi in glioblastoma cell chemoresistance. PKCi was found to confer partial resistance to cisplatin, a widely used chemotherapy agent. Microarray analysis of gene expression identified a novel linkage between PKCi and the p38 mitogen-activated protein kinase (MAP kinase) pathway that contributes to glioblastoma cell chemoresistance.
Results
PKCi depletion by RNA interference Expression of aPKCs in U87MG cells was initially characterized by RT-PCR. Using mRNA prepared from U87MG glioblastoma cells as template, RT-PCR with the primer pair IOTA1 and IOTA2 (see Materials and methods) gave a product of the expected size (data not shown). Sequencing of the PCR product confirmed that PKCi cDNA had been amplified. RT-PCR using U87MG mRNA and two different primer pairs for PKCz did not give any PCR products, although both primer pairs gave products of the expected size when a plasmid containing the cDNA for PKCz was used as template. U87MG cells therefore express PKCi mRNA, but no detectable PKCz mRNA.
To assess the role of PKCi in human glioblastoma cells, RNA interference was used to reduce PKCi levels in U87MG cells. Two RNA duplexes, designated siPKCiA (sense strand sequence GUGCAUCAACUG-CAAACUC) and siPKCiB (sense strand sequence UGAGGUUCGAGACAUGUGU), were synthesized. Each strand contained a 3 0 overhang of two 2-deoxythymidines. BLAST searches (Altschul et al., 1997) with the sense sequence of each of these duplexes showed that there were no exact matches to either sequence in the GenBank, EMBL, DDBJ and PDB databases, other than PKCi itself. U87MG glioblastoma cells were transfected with a random control RNA duplex or the siPKCiA RNA duplex, and levels of PKCi mRNA were assessed by quantitative PCR. This showed that the siPKCiA duplex reduced PKCi mRNA levels by 7574% 2 days after transfection (data not shown). Western blot analysis showed that PKCi protein levels were also reduced 2 days after transfection in both U87MG cells ( Figure 1A ) and a second human glioblastoma cell line, A172 ( Figure 1B) . A similar level of depletion was maintained at 3 days after transfection (the longest time point examined, data not shown). Western blot analyses of different amounts of cell extract showed that PKCi levels were reduced by 75-90% in different experiments ( Figure 1E ). The effects on PKCi mRNA and protein levels were seen using concentrations of RNA duplex below those reported to cause nonspecific effects in other systems (Semizarov et al., 2003) . The second RNA duplex, siPKCiB, also reduced the levels of PKCi in both U87MG and A172 cells (Figure 1C and D) . However, on average this duplex did not deplete PKCi protein levels as effectively Different amounts of total cell lysate from U87MG cells transfected with a random RNA duplex (control), siPKCiA or siPKCiB were analysed by Western blotting for levels of PKCi and ERK (as a loading control). (F and G) U87MG cells (F) and A172 cells (G) treated as above were analysed by Western blotting with an antibody that recognizes PKCa, PKCbI and PKCbII, with an antibody that recognizes PKCd, and with an antibody to ERK (used as a loading control).
as the siPKCiA duplex ( Figure 1E ). Protein levels of other PKC family members examined (PKCa, PKCbI, PKCbII and PKCd) were unaffected by RNA interference targeted to PKCi ( Figure 1F and G). Microarray analysis data also showed that mRNA levels for other PKC members were unaffected (see below).
PKCi depletion sensitizes glioblastoma cells to cisplatin
To determine whether PKCi conferred resistance to cell death induced by chemotherapy agents, U87MG cells were transfected with random or siPKCiA RNA duplexes and then treated with the chemotherapy agent cisplatin. Depletion of PKCi resulted in sensitization of U87MG glioblastoma cells to cisplatin, as assessed by 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays (Figure 2a) . The IC 50 for cisplatin on U87MG cells was 60 mg/ml for mock and control RNA duplex-transfected cells, and 30 mg/ml for siPKCiA transfected cells. Cisplatin potency has been reported to be very different depending on the cell culture media used (Hanigan et al., 2005) ; these values were all determined using the cell culture conditions described in Materials and methods. Further experiments were performed using a cisplatin concentration of 20 mg/ml, as the difference in cytotoxicity between control and PKCi-depleted cells was pronounced at this concentration. Figure 2b -g shows the morphology of cell treated with cisplatin with or without PKCi depletion. Cells that were depleted of PKCi and treated with cisplatin were more rounded up and exhibited more blebbing than cells treated with cisplatin alone, or depleted of PKCi only. Determination of live cell counts showed that PKCi depletion with either siPKCiA or siPKCiB significantly enhanced the cytotoxicity of cisplatin, in both U87MG cells (Figure 2h and j) and A172 cells (Figure 2i and k) . Flow cytometry was used to directly assess effects of PKCi depletion on apoptosis. PKCi depletion on its own had no effects on levels of apoptosis in U87MG cells (data not shown). PKCi depletion did significantly increase the amount of apoptosis induced by 20 mg/ml cisplatin compared to that seen in mock or control RNA duplex-transduced cells. This was seen in both A172 cells (Figure 3a -d) and U87MG cells (Figure 3e ). These results show that PKCi has a role in protecting U87MG glioblastoma cells from apoptosis induced by cisplatin.
Effects of PKCi on activation of the NFkB pathway
The atypical PKC-mediated chemoresistance seen in leukemia cells was shown to be due to its role in the activation of the NFkB pathway (Lu et al., 2001) . To determine if the same mechanism functioned in glioblastoma cells, the effects of PKCi depletion on NFkB activation was assayed. Levels of the NFkB inhibitor IkBa, which is rapidly degraded upon activation of this pathway, were used as readout. Treatment of U87MG cells with tumor necrosis factor a (TNFa) caused a rapid degradation of IkBa ( Figure 4A ). This was seen within 10 min after exposure; levels of IkBa started to recover after 60 min, probably because of the enhanced IkBa transcription that is known to occur with prolonged stimulation of this pathway (Le Bail et al., 1993) . Depletion of PKCi had no effects on the kinetics of IkBa degradation and recovery. Cisplatin did not induce the degradation of IkBa in U87MG cells ( Figure 4B ), although activation of NFkB by chemotherapy has been reported in other cell types (Mayo and Baldwin, 2000) .
As a second method to assess NFkB activity, control or PKCi-depleted cells were transfected with an NFkB reporter plasmid. PKCi depletion had no significant effect on basal or TNFa-stimulated NFkB activity ( Figure 4C ). Taken together, these data show that NFkB pathway activation was not grossly affected by PKCi depletion, and that enhanced activation of the NFkB pathway is not a major mechanism for PKCimediated chemoresistance in glioblastoma cells.
Microarray analysis of PKCi-mediated resistance to cisplatin
To screen for other possible mechanisms by which PKCi could confer resistance to cisplatin, microarray analysis of gene expression was performed, as described in Materials and methods. Four conditions were analysed: (i) U87MG cells transfected with a control RNA duplex; (ii) U87MG cells transfected with a control RNA duplex and treated for 6 h with cisplatin; (iii) U87MG cells transfected with a siPKCiA RNA duplex; (iv) U87MG cells transfected with a siPKCiA RNA duplex and treated for 6 h with cisplatin. This experiment was performed in triplicate on the same day. RNA was isolated, converted to cDNA, in vitro transcribed and hybridized to the Human Genome U133 set of microarray chips as described in Materials in methods. The Affymetrix Human Genome U133 Set is designed to analyse the expression of greater than 33 000 human genes (www.affymetrix.com). All comparisons described below are between means derived from the three independent experiments. As one initial test of the quality of the data, the changes in levels of PKCi mRNA determined by this method were checked. The levels of PKCi decreased 8.3-fold in siPKCiA-transfected cells compared to the control RNA duplextransfected cells (an 88% decrease) ( Figure 5B ). PKCi mRNA also decreased 8.1-fold in siPKCiA-transfected cells treated with cisplatin compared to the control RNA duplex-transfected cells (data not shown). This is in agreement with data from qRT-PCR analysis and Western blot analysis described above. Both changes were deemed significant by SAM (Tusher et al., 2001 ) at a False Discovery Rate of 0.05. In terms of specificity of the siPKCiA RNA duplex, hybridization values for probe sets corresponding to other PKC family members did not change significantly ( Figure 5A ). One exception to this was probe set 215195_at, one of the three probe sets for PKCa. Since 215195_at hybridizes at a much lower level than another probe set for this gene, 213093_at, which is unchanged, 215195_at hybridization probably does not accurately represent PKCa mRNA levels. This is supported by the unchanged protein levels of PKCa ( Figure 1F and G).
The microarray strategy was designed to identify sets of genes that were: (i) regulated by basal PKCi function; (ii) regulated by cisplatin; (iii) regulated by cisplatin in a PKCi-dependent fashion. This study focuses on the set of genes regulated by basal PKCi function. SAM was used to identify genes that were differentially expressed in PKCi-depleted samples as compared with controls ( Figure 5B ). Out of 4897 probe sets that were identified as significantly changed on HG-U133A (FDR ¼ 0.05), overall decreases greater than twofold were detected in 354 probe sets; 19 of these exhibited decreases of more than fivefold, while the maximum decrease in expression observed was 12-fold. Significant increases greater than twofold were detected with 1389 probe sets; 143 of these exhibited increases of more than fivefold, while the maximum increase in expression was 34-fold. These data suggest that PKCi influences cell behavior more by repression, rather than activation, of gene transcription. For both activation and repression, no obvious single class of genes with related functions was affected.
PKCi represses glia maturation factor b expression
The stress-activated kinase p38 MAP kinase has been shown to mediate cisplatin cytotoxicity in various cancer cell lines (Losa et al., 2003) . Microarray analysis showed that PKCi depletion increased the levels of glia maturation factor b (GMFb), a protein which has previously shown to be an enhancer of p38 MAP kinase signaling ( Figure 5B ) (Lim and Zaheer, 1996) . This suggested that PKCi could protect cells from apoptosis by preventing GMFb-mediated enhancement of p38 MAP kinase signaling. To determine whether changes in GMFb mRNA levels led to changes in protein expression, Western blot analysis of GMFb was performed on cells treated with cisplatin in the absence or presence of PKCi depletion. This showed that PKCi depletion also caused an increase in GMFb protein levels ( Figure 6a and b); this was seen with the two different RNAi duplexes against PKCi.
PKCi attenuates p38 MAP kinase signaling Total cell extracts from control or siPKCiA-transfected cells treated with cisplatin were also probed for levels of p38 MAP kinase, extracellular signal-regulated kinase (ERK), and their activated, phosphorylated forms. Cisplatin caused an increase in both phosphorylated p38 MAP kinase and ERK, as described previously in other cell types (Losa et al., 2003; Choi et al., 2004) (Figure 6c and d) . In cells depleted of PKCi, basal levels of phosphorylated p38 MAP kinase were similar to control duplex-transfected cells; however, cisplatin consistently induced higher levels of p38 MAP kinase phosphorylation relative to cells with normal levels of PKCi. Levels of activated ERK were, in contrast, decreased.
GMFb enhances p38 MAP kinase signaling and cisplatin cytotoxicity A retroviral vector was constructed that expressed GMFb under control of the CMV promoter as described in Materials and methods. Transient transfection of this construct into 293T cells showed that it was able to drive expression of GMFb. However, retroviral transduction of U87MG cells followed by puromycin selection did not give any resistant cells while empty control vector did, suggesting that sustained high overexpression of GMFb is toxic to U87MG cells. This has been reported previously for other cell types, and is consistent with a proapoptotic function for GMFb (Kaimori et al., 2003) . To circumvent this problem, U87MG cells were transiently transfected with the GMFb-expressing vector. This induced some cell death on its own, but enough cells survived to allow the analysis of effects of GMFb expression on p38 MAP kinase activity and cisplatin cytotoxicity. The GMFb transgene protein product was larger in size than the endogenous GMFb, due to the introduction of an inframe upstream initiation site and an additional 14 amino-terminal codons during subcloning (Figure 7a) . Cells expressing the GMFb transgene showed an increased level of p38 MAP kinase phosphorylation in response to cisplatin. Overall levels of p38 MAP kinase were either unaffected or reduced in different experiments. Expression of the GMFb transgene also consistently caused a partial sensitization of cells to cisplatin cytotoxicity, as assessed by cell counts (Figure 7b ). The extent of the sensitization was less than seen with PKCi depletion; this may be due to differences in the level of GMFb expression in the GMFb transient transfections, as compared to the Table showing the 50 probe sets whose hybridization values changed most significantly between the two types of samples according to SAM (false discovery rate ¼ 3.2%). Hybridization values (control and siPKCiA) are expressed on a log2 scale. Fold change ratios were calculated between the average hybridization values of probe sets in the control replicates and in the siPKCiA-depleted replicates; values above one point to genes that are upregulated upon depletion of siPKCiA, and values below one point to genes that are downregulated upon depletion of siPKCiA. As expected, one of the significantly downregulated hybridization values is for a probe set corresponding to PKCi (with a fold change of 0.12). A probe set for GMFb also shows a fold change in hybridization value of 13.42 indicating strong upregulation upon PKCi depletion. The original. CEL files for the six samples can be downloaded from http://www.ogic.ca/projects/Baldwin05/. p38 MAP kinase mediates the enhanced cisplatin cytotoxicity seen with PKCi depletion To determine if p38 MAP kinase had a role in the enhanced cisplatin-induced cell death seen with PKCi depletion, U87MG cells were treated with the p38 MAP kinase inhibitor SKF86002, which is active against all four p38 MAP kinase family members (Losa et al. 2003) . Pretreatment with this drug effectively blocked the increase in cisplatin-induced cell death seen in PKCidepleted cells, as assessed by both MTT assays ( Figure 8a ) and flow cytometry (Figure 8b ).
Discussion
The data presented here show that PKCi confers partial resistance to cisplatin. This was observed in two different human glioblastoma cell lines. While other studies have shown a role for PKCi in chemoresistance, the chemoresistance seen in glioblastoma cells appeared to be mechanistically different, as NFkB pathway activation was not affected by PKCi depletion. This conclusion was based on the fact that PKCi depletion did not obviously affect TNFa-induced degradation of IkBa, and also did not affect basal or TNFa-induced NFkB activity. This result is in agreement with results reported recently for PKCi knockout mice (Soloff et al., 2004) . There is clear evidence from PKCz knockout mice that this enzyme is involved in NFkB activation (Leitges et al., 2001) ; it therefore appears likely that only the PKCz enzyme, and not PKCi, has a role in NFkB activation. If this is the case, the fact that the glioblastoma cells used here do not express PKCz would provide a simple explanation for a lack of any NFkB activation in response to cisplatin and the lack of any apparent role for NFkB in cisplatin chemoresistance.
The experiments described here define a novel mechanism by which PKCi can protect cells from cisplatin. This is based on the finding from microarray analysis that PKCi negatively regulates the expression of GMFb mRNA. Although originally thought to be an extracellular peptide, GMFb is now known to be an intracellular protein that is found primarily in the brain, but also in other tissues including the lung, spleen, colon, thymus and kidney (Kaimori et al., 2003; Inagaki et al., 2004) . GMFb has an important role in the normal brain, as knockout mice that do not express GMFb, although viable, show defects in motor performance and learning . This beneficial effect comes at a price, as GMFb sensitizes both astrocytes and proximal tubular kidney cells to oxidative injury (Kaimori et al., 2003; Zaheer et al., 2004) . At least part of this sensitization is due to GMFb's ability to enhance p38 MAP kinase activity (Kaimori et al., 2003; Zaheer et al., 2004 ), which appears to involve a physical association between GMFb and this kinase in cells (Lim and Zaheer, 1996) .
The regulation of GMFb mRNA by PKCi also led to changes in GMFb protein expression. This was seen with two different RNA duplexes specific for PKCi, providing strong evidence that PKCi is responsible for this effect. This repression of GMFb gene expression by PKCi may occur either by a direct mechanism, or indirectly as a consequence of the regulation of other genes. As GMFb has been shown to enhance p38 MAP kinase signaling (Lim and Zaheer, 1996) , it was predicted that the increase in GMFb levels upon PKCi depletion would lead to an enhanced p38 MAP kinase activation in response to cisplatin. This was the case, as cisplatin-activated p38 MAP kinase to a greater extent in cells depleted of PKCi. This result is consistent with previous observations on the effect of atypical PKC inhibition by Par-4, an endogenous inhibitor of PKCz and PKCi (Berra et al., 1997; Garcia-Cao et al., 2003) ; inhibition of PKCi by this method also enhanced p38 MAP kinase signaling. Overexpression of GMFb in U87MG cells reproduced the effects of PKCi depletion on both p38 MAP kinase activation and cisplatin cytotoxicity. PKCi-mediated repression of GMFb expression is therefore sufficient to account for these effects. Pharmacological blockade of p38 MAP kinase signaling blocked the increase in cell death seen in PKCi-depleted cells, showing that attenuation of p38 MAP kinase signaling by PKCi is necessary and sufficient for its effects on cisplatin cytotoxicity. Other groups have reported that the MEK inhibitor PD98059, which blocks ERK activation, sensitizes glioblastoma cells to cisplatin (Zhan and O'Rourke, 2004) . PKCi depletion decreased ERK activation by cisplatin, suggesting that this might be a second mechanism by which PKCi could affect cisplatin cytotoxicity. However, this did not appear to be the case, as the effects of PKCi depletion were completely reversed by p38 MAP kinase inhibition. It is possible that the magnitude of the effects of PKCi depletion on ERK activation is not sufficient for this to be a major factor. p38 MAP kinase inhibition did not completely inhibit cisplatin cytotoxicity, suggesting that other mechanisms also contribute to the toxicity of this drug in glioblastoma. Overexpression of PKCi in U87MG cells did not further repress GMFb levels (data not shown). Consistent with the mechanism we have shown here, PKCi overexpression also did not increase resistance to cisplatin further. A likely explanation for this is that PKCi downstream signaling is already saturated, so that further increases in PKCi signaling do not make any difference.
The repression of GMFb expression, leading to attenuation of proapoptotic p38 MAP kinase signaling, is one mechanism by which PKCi can repress apoptosis. This presumably can function in concert with, or independently of, other anti-apoptotic pathways mediated by PKCi. These include the recently described function of PKCi in phosphorylating and inactivating the proapoptotic protein Bad (Jin et al., 2005) . The suppression of GMFb expression by PKCi also potentially provides a mechanism by which glioblastoma cells can protect themselves from oxidative damage, based on the established role of GMFb in oxidative stress. While oxidative damage is thought to be mutagenic, and therefore tumor promoting, in the early stages of cancer, in later stages of tumor growth oxidative damage limits the growth of tumor cells (Benhar et al., 2002) . While more studies would be required to validate this, PKCimediated suppression of GMFb may be a mechanism by which the PI 3-kinase pathway prevents oxidative damage-induced senescence in glioblastoma cells.
The microarray analysis performed here also identified a large number of other genes that are potentially regulated by PKCi. A survey of the data shows that these genes do not fall into any one particular classinstead the data suggest that PKCi is very pleiotropic in its cellular function. PKCi appears to affect the expression of mRNAs for a wide array of other signaling molecules, including members of the CCN family (CCN3/NOV, CCN5/WISP2) (Brigstock, 2003) and the Wnt coreceptor RYK (Lu et al., 2004) . This suggests that, aside from the linkage between PKCi and p38 MAP kinase described here; there is crosstalk between PKCi and multiple other signaling pathways in glioblastoma cells. 
Materials and methods

Chemicals and antibodies
Cell lines
The human glioblastoma cell line U87MG was obtained from Dr W Cavenee (Ludwig Institute for Cancer Research, La Jolla, CA, USA). A172 cells were from the American Type Culture Collection. Both these cell lines are wild type for p53, mutant for PTEN and mutated at the INK4A/ARF locus (Ishii et al., 1999) ; this set of mutations is common in de novo glioblastoma (Holland, 2001) . Cells were cultured at 371C and 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM glutamine and 10% (v/v) of a 2:1 mixture of donor bovine serum and fetal bovine serum.
RT-PCR
PolyA þ mRNA was isolated from cells using the MicroFastTrack 2.0. mRNA Isolation Kit (Invitrogen, Carlsbad, CA, USA). First strand cDNA synthesis was performed with the cDNA Cycle Kit (Invitrogen, Carlsbad, CA, USA). The following primer pairs were used for PCR: for PKCz the primer pair PKCZ5 CCCAAGATGGAAGGGAGCGGC GGC and PKCZA CCGACTAGTCGTCTGGAAGCAGG AGTG also the primer pair PKCZB ACGACTAGTCGG TTGTTCCTGGTCATTGAG and PKCZ3 GCCTCACACC GACTCCTCGGTGGACAG; for PKC i the primer pair IOTA1 ACCATGTCCCACACGGTCGCAGGC and IOTA2 ATCCTGAAGACCTAGACTGGATGAAGC. For quantitative RT-PCR, total RNA was isolated using RNEasy Mini Kits (Qiagen Inc., Mississauga, ON, Canada) and cDNA was synthesized using First Strand cDNA Synthesis Kits (MBI Fermentas, Burlington, ON, Canada) using random hexamer primers. Quantitative PCR was performed in a LightCycler (Roche, Basel, Switzerland) using FastStart DNA Master SYBR Green I kits (Roche, Basel, Switzerland). MgCl 2 concentrations and PCR temperatures and cycle times were optimized for each primer pair used. Data were analysed using LightCycler analysis software (Roche, Basel, Switzerland) . For quantitative PCR of PKCi the primer pair IOTAL (CGGCATGTGTAAGGAAGGAT) and IOTAR (TCGGAG CTCCCAACAATATC) was used; for b 2-microglobulin, used as a reference gene, the primer pair B2MFOR (TGCTGTCTCCATGTTTGATGTATCT) and B2MREV (TCTCTGCTCCCCACCTCTAAGT) was used.
RNA transfections RNA duplexes were obtained from Dharmacon Research Inc. (Lafayette, CO, USA). Two control duplexes were used: the first had the sense RNA sequence GCGCGCUUUGUAGGAUUCGdTdT (Scramble II duplex, Dharmacon Research Inc.) and the second had the sense RNA sequence AUU-CUAUCACUAGCGUGACUU (nonspecific control duplex X (42% GC content), also from Dharmacon Research Inc.). RNA duplex concentrations were determined by measuring absorbance at 260 nm and calculating concentrations using extinction coefficients provided by the manufacturer. Glioblastoma cells were plated in six-well dishes at a density of 100 000 cells/plate the day before transfection, in DMEM supplemented with 10% serum and no antibiotics. On the day of transfection, 10 ml of RNA duplex solution was added to 175 ml OptiMEM I (Invitrogen Canada Inc., Burlington, ON, Canada). In a separate tube, 4 ml of Oligofectamine (Invitrogen Canada Inc., Burlington, ON, Canada) was added to 11 ml of OptiMEM I. This was mixed gently and incubated 10 min at room temperature. The diluted Oligofectamine was then added to the RNA duplex in OptiMEM I and incubated for another 20 min at room temperature after gentle mixing. Media was removed from the cells, and the cells were washed once with 3 ml of warm OptiMEM I. 800 ml of OptiMEM I was added per well, and the Oligofectamine/RNA duplex mix was then added (200 ml per well) and mixed by rocking the plate from side-side for 30 s. Final concentrations of RNA in the transfections were 5.3 nM of siPKCiA and 20 nM for siPKCiB. Control RNA concentrations were matched to the specific siRNA duplex used. Cells were incubated 4 h at 371C, after which 2 ml of DMEM supplemented with 10% serum was added. For transfections in 10 cm plates ad 96-well plates, cells were plated at densities of 1 Â 10 6 and 1 Â 10 4 cells/well, respectively, and reagent volumes were adjusted accordingly.
Western blot analysis
Western blotting was performed as described previously (Lorimer and Lavictoire, 2000) . After electrophoretic transfer from the gel, membranes were stained with amido black to confirm that equal sample loading and transfer was achieved.
MTT assays Cells in 96-well tissue culture plates were transfected with RNA duplexes as above.At 48 h after transfection, the media was replaced with 100 ml of media containing increasing concentrations of cisplatin (0-80 mg/ml). After 24 h, cell survival was assessed using the MTT (3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. Cells were exposed to 25 ml of MTT (5 mg/ml in sterile PBS, SigmaAldrich, Canada) and incubated for 2-3 h at 371C and 5% CO 2 . The formazan product was formed and dissolved by adding 100 ml of lysis buffer (20% SDS (BioShop Canada Inc., Burlington, ON, Canada)) and DMF (VWR International, Mississauga, ON, Canada). Absorbance was measured at 570 nm in a Dynex MRX microplate reader. Background values were determined by carrying out the assay in wells containing media without cells.
Cell counts
Live cell number was determined using a Beckmann Coulter counter (Beckman Coulter Canada Inc., Mississauga, ON, Canada).
Flow cytometry
After transfection with different RNA duplexes, adherent and nonadherent cells were harvested and fixed with 70% (v/v) ethanol in PBS. Cell nuclei were stained with propidium iodide and DNA content was analysed by flow cytometry using a BD LSR flow cytometer (Becton Dickinson, San Jose, CA, USA). Data acquisition was performed using Cell Quest software (Becton Dickinson, San Jose, CA, USA) and the data were analysed using Mod Fit LT software (Verity Software House Inc., Sopsham, ME, USA).
Reporter plasmid assay for NFkB activity Cells in six-well tissue culture plates were transfected with RNA duplexes as above. At 24 h after RNA transfection, cells were cotransfected with 3 mg of the reporter plasmid pNF-kB-Luc (Stratagene) and 3 ng pRL-CMV (Promega), which contains the CMV promoter upstream of the Renilla luciferase gene, to serve as an internal control for transfection efficiency. Transfections were performed using GeneJuice Transfection Reagent (Novagen, Madison, WI, USA) as recommended by the manufacturer. At 24 h following DNA transfection, the culture media was replaced with 1 ml of media containing 20 ng/ml of TNFa. The cells were then harvested at various times, 0, 1 and 6 h after treatment. Firefly and Renilla luciferase assays were performed using the Dual-Luciferase Reporter Assay System (Promega, Madison WI, USA). Samples were analysed on a EG&G Berthold Lumat LB9507 luminometer (Berthold Technologies, Bad Wildbad, Germany).
Microarray analysis
RNA was isolated from cells on 10 cm plates using Qiagen RNEasy kits (Qiagen Inc, Mississauga, ON, Canada) according to the manufacturer's protocol for total RNA isolation from animal cells. RNA was converted to cDNA, in vitro transcribed and hybridized to the Human Genome U133 Set of microarray chips (Affymetrix, Santa Clara, CA, USA) at the Ontario Genomics Innovation Centre, Ottawa, Canada.
Microarray data analysis
Expression values were computed from CEL. files by applying GCRMA (v1.1.3) under R (v2.0.0) (http://www.r-project.org/) within sets of replicate samples. Statistical testing was performed with the significance analysis of microarrays (SAM) (Tusher et al., 2001 ) function in SIGGENES (v1.2.11). The GCMRA and SIGGENES packages are part of the Bioconductor project (Gentleman et al., 2004) . Expression data will be deposited in the Gene Expression Omnibus database (GEO) (http://www.ncbi.nlm.nih.gov/geo/).
Construction of GMFb expression vector
Full-length cDNA for human GMFb was obtained from the American Type Culture Collection (MGC-12462). The cDNA was isolated after digestion with EcoRI and NotI, and ligated into the retroviral vector pLPCX (Clontech, Palo Alto, CA, USA) that had been digested with the same restriction enzymes. Retrovirus containing GMFb cDNA was made as described previously (Lorimer and Lavictoire, 2000) . For transient overexpression of GMFb in U87MG cells, transfections were performed using GeneJuice Transfection Reagent (Novagen, Madison, WI, USA).
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